• The Future of Psychedelics: A Discussion with Rick Doblin & Steven Levine

  • 2021/09/29
  • 再生時間: 1 時間 4 分
  • ポッドキャスト

The Future of Psychedelics: A Discussion with Rick Doblin & Steven Levine

  • サマリー

  • In this episode, Dr. Jeffrey Lieberman is joined by pioneering psychedelics researchers, Drs. Rick Doblin and Steven Levine, to discuss the therapeutic applications of psychedelic drugs such as psilocybin, ketamine, LSD, MDMA, and ibogaine in treating mental health and addiction disorders, and the future path forward in legitimately harnessing their game changing potential.

    Dr. Rick Doblin is the Founder and Executive Director of MAPS (the Multidisciplinary Association for Psychedelic Studies), , a leading non-profit psychedelic drugs research and educational organization, with both domestic and international studies.

    Dr. Steven Levine is the Vice President of Patient Access at COMPASS Pathways, a leading psychedelics research organization conducting international clinical trials with psilocybin therapy for treatment-resistant depression. A pioneer in the clinical use of IV ketamine for treatment resistant depression, Dr. Levine is also the founder of Actify Neurotherapies, one of the largest networks of ketamine treatment centers in the US.

    続きを読む 一部表示

あらすじ・解説

In this episode, Dr. Jeffrey Lieberman is joined by pioneering psychedelics researchers, Drs. Rick Doblin and Steven Levine, to discuss the therapeutic applications of psychedelic drugs such as psilocybin, ketamine, LSD, MDMA, and ibogaine in treating mental health and addiction disorders, and the future path forward in legitimately harnessing their game changing potential.

Dr. Rick Doblin is the Founder and Executive Director of MAPS (the Multidisciplinary Association for Psychedelic Studies), , a leading non-profit psychedelic drugs research and educational organization, with both domestic and international studies.

Dr. Steven Levine is the Vice President of Patient Access at COMPASS Pathways, a leading psychedelics research organization conducting international clinical trials with psilocybin therapy for treatment-resistant depression. A pioneer in the clinical use of IV ketamine for treatment resistant depression, Dr. Levine is also the founder of Actify Neurotherapies, one of the largest networks of ketamine treatment centers in the US.

The Future of Psychedelics: A Discussion with Rick Doblin & Steven Levineに寄せられたリスナーの声

カスタマーレビュー:以下のタブを選択することで、他のサイトのレビューをご覧になれます。